The clinical value of serum CRP has also been explored in tumor settings, such as ovarian cancer, breast cancer, colorectal cancer, lung cancer, prostate cancer, renal cell carcinoma, and pancreatic cancer (24–31). This evidence concerns the gene CRP and renal cell carcinoma.